The 3 DSMB reports thus far indicate that RVX-208 is not causing any safety issues or other problems that are otherwise observed in the placebo group. In my opinion, these DSMB reports do not give any information regarding efficacy. Preliminary efficacy will be assessed by the DSMB at 125 events as part of the planned futility analysis. Once the futility analysis is completed, I expect this data to remain confidential and not shared with Resverlogix, the Clinical Advisory Board, or study clinicians. In my opinion, Resverlogix will likely simply be told to proceed as planned, stop or possibly modify the trial. This statement will likely be communicated to shareholders via a press release. 

BearDownAZ